FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1962392014> ?p ?o ?g. }

• W1962392014 abstract "Interleukin 2 receptor antagonists (IL2Ra) are used as induction therapy for prophylaxis against acute rejection in kidney transplant recipients. Use of IL2Ra has increased steadily since their introduction, but the proportion of new transplant recipients receiving IL2Ra differs around the globe, with 27% of new kidney transplant recipients in the United States, and 70% in Australasia receiving IL2Ra in 2007.To systematically identify and summarise the effects of using an IL2Ra, as an addition to standard therapy, or as an alternative to another immunosuppressive induction strategy.We searched the Cochrane Renal Group's specialised register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE to identify new records, and authors of included reports were contacted for clarification where necessary.Randomised controlled trials (RCTs) in all languages comparing IL2Ra to placebo, no treatment, other IL2Ra or other antibody therapy.Data was extracted and assessed independently by two authors, with differences resolved by discussion. Dichotomous outcomes are reported as relative risk (RR) and continuous outcomes as mean difference (MD) with 95% confidence intervals (CI).We included 71 studies (306 reports, 10,537 participants). Where IL2Ra were compared with placebo (32 studies; 5,784 patients) graft loss including death with a functioning graft was reduced by 25% at six months (16 studies: RR 0.75, 95% CI 0.58 to 0.98) and one year (24 studies: RR 0.75, 95% CI 0.62 to 0.90), but not beyond this. At one year biopsy-proven acute rejection was reduced by 28% (14 studies: RR 0.72, 95% CI 0.64 to 0.81), and there was a 19% reduction in CMV disease (13 studies: RR 0.81, 95% CI 0.68 to 0.97). There was a 64% reduction in early malignancy within six months (8 studies: RR 0.36, 95% CI 0.15 to 0.86), and creatinine was lower (7 studies: MD -8.18 micromol/L 95% CI -14.28 to -2.09) but these differences were not sustained.When IL2Ra were compared to ATG (16 studies, 2211 participants), there was no difference in graft loss at any time point, or for acute rejection diagnosed clinically, but the was benefit of ATG therapy over IL2Ra for biopsy-proven acute rejection at one year (8 studies:, RR 1.30 95% CI 1.01 to 1.67), but at the cost of a 75% increase in malignancy (7 studies: RR 0.25 95% CI 0.07 to 0.87) and a 32% increase in CMV disease (13 studies: RR 0.68 95% CI 0.50 to 0.93). Serum creatinine was significantly lower for IL2Ra treated patients at six months (4 studies: MD -11.20 micromol/L 95% CI -19.94 to -2.09). ATG patients experienced significantly more fever, cytokine release syndrome and other adverse reactions to drug administration and more leucopenia but not thrombocytopenia. There were no significant differences in outcomes according to cyclosporine or tacrolimus use, azathioprine or mycophenolate, or to the study populations baseline risk for acute rejection. There was no evidence that effects were different according to whether equine or rabbit ATG was used.Given a 38% risk of rejection, per 100 recipients compared with no treatment, nine recipients would need treatment with IL2Ra to prevent one recipient having rejection, 42 to prevent one graft loss, and 38 to prevent one having CMV disease over the first year post-transplantation. Compared with ATG treatment, ATG may prevent some experiencing acute rejection, but 16 recipients would need IL2Ra to prevent one having CMV, but 58 would need IL2Ra to prevent one having malignancy. There are no apparent differences between basiliximab and daclizumab. IL2Ra are as effective as other antibody therapies and with significantly fewer side effects." @default.
• W1962392014 created "2016-06-24" @default.
• W1962392014 creator A5024929421 @default.
• W1962392014 creator A5032903282 @default.
• W1962392014 creator A5038938109 @default.
• W1962392014 creator A5039834479 @default.
• W1962392014 creator A5039925106 @default.
• W1962392014 creator A5051855419 @default.
• W1962392014 creator A5056074771 @default.
• W1962392014 creator A5060409834 @default.
• W1962392014 date "2010-01-20" @default.
• W1962392014 modified "2023-10-06" @default.
• W1962392014 title "Interleukin 2 receptor antagonists for kidney transplant recipients" @default.
• W1962392014 cites W1526492522 @default.
• W1962392014 cites W1547131877 @default.
• W1962392014 cites W1553403936 @default.
• W1962392014 cites W1567214956 @default.
• W1962392014 cites W1569506958 @default.
• W1962392014 cites W1595184853 @default.
• W1962392014 cites W1598602811 @default.
• W1962392014 cites W1665088674 @default.
• W1962392014 cites W1756759934 @default.
• W1962392014 cites W1947608532 @default.
• W1962392014 cites W1965286410 @default.
• W1962392014 cites W1967915560 @default.
• W1962392014 cites W1969084333 @default.
• W1962392014 cites W1969660029 @default.
• W1962392014 cites W1970626700 @default.
• W1962392014 cites W1975661078 @default.
• W1962392014 cites W1976022880 @default.
• W1962392014 cites W1978195383 @default.
• W1962392014 cites W1983211062 @default.
• W1962392014 cites W1983298945 @default.
• W1962392014 cites W1985137297 @default.
• W1962392014 cites W1985570047 @default.
• W1962392014 cites W1986174774 @default.
• W1962392014 cites W1987264461 @default.
• W1962392014 cites W1987532648 @default.
• W1962392014 cites W1987732789 @default.
• W1962392014 cites W1987847046 @default.
• W1962392014 cites W1989468146 @default.
• W1962392014 cites W1990423961 @default.
• W1962392014 cites W1991268249 @default.
• W1962392014 cites W1991331800 @default.
• W1962392014 cites W1991374011 @default.
• W1962392014 cites W1991704115 @default.
• W1962392014 cites W1992241917 @default.
• W1962392014 cites W1993758901 @default.
• W1962392014 cites W1995281516 @default.
• W1962392014 cites W1996431651 @default.
• W1962392014 cites W1999124343 @default.
• W1962392014 cites W1999298846 @default.
• W1962392014 cites W2000138932 @default.
• W1962392014 cites W2000442546 @default.
• W1962392014 cites W2000531481 @default.
• W1962392014 cites W2001388552 @default.
• W1962392014 cites W2002713380 @default.
• W1962392014 cites W2003329996 @default.
• W1962392014 cites W2006679408 @default.
• W1962392014 cites W2008102785 @default.
• W1962392014 cites W2009372903 @default.
• W1962392014 cites W2010756406 @default.
• W1962392014 cites W2010903679 @default.
• W1962392014 cites W2011221735 @default.
• W1962392014 cites W2011256495 @default.
• W1962392014 cites W2013283804 @default.
• W1962392014 cites W2014307037 @default.
• W1962392014 cites W2015895464 @default.
• W1962392014 cites W2017730031 @default.
• W1962392014 cites W2019094511 @default.
• W1962392014 cites W2019177796 @default.
• W1962392014 cites W2019626693 @default.
• W1962392014 cites W2020405446 @default.
• W1962392014 cites W2023095312 @default.
• W1962392014 cites W2025287011 @default.
• W1962392014 cites W2025749715 @default.
• W1962392014 cites W2025863518 @default.
• W1962392014 cites W2026304323 @default.
• W1962392014 cites W2026959355 @default.
• W1962392014 cites W2028025188 @default.
• W1962392014 cites W2028113790 @default.
• W1962392014 cites W2028348578 @default.
• W1962392014 cites W2031246665 @default.
• W1962392014 cites W2034435374 @default.
• W1962392014 cites W2035011431 @default.
• W1962392014 cites W2035458828 @default.
• W1962392014 cites W2037679645 @default.
• W1962392014 cites W2037937957 @default.
• W1962392014 cites W2039736681 @default.
• W1962392014 cites W2046288760 @default.
• W1962392014 cites W2047179014 @default.
• W1962392014 cites W2047335435 @default.
• W1962392014 cites W2047662663 @default.
• W1962392014 cites W2047723007 @default.
• W1962392014 cites W2047807183 @default.
• W1962392014 cites W2051554858 @default.
• W1962392014 cites W2052228881 @default.
• W1962392014 cites W2056109287 @default.
• W1962392014 cites W2056577857 @default.
• W1962392014 cites W2056731689 @default.

• next